Home > Insider Trading > Filing (0001209191-14-012246)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1419600	Flexion Therapeutics Inc	FLXN	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1597789	Rafael Tordjman	C/O Flexion Therapeutics, Inc. 10 Mall Road, Suite 301 Burlington MA 01803		Yes	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2014-02-18	1,614,382	$0.00	1,614,382	No	4	C	Indirect	By Sofinnova Capital VI FCPR
Common Stock	Acquisiton	2014-02-18	260,340	$0.00	1,874,722	No	4	C	Indirect	By Sofinnova Capital VI FCPR
Common Stock	Acquisiton	2014-02-18	230,769	$13.00	2,105,491	No	4	P	Indirect	By Sofinnova Capital VI FCPR

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	By Sofinnova Capital VI FCPR
No	4	C	Indirect	By Sofinnova Capital VI FCPR
No	4	P	Indirect	By Sofinnova Capital VI FCPR

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2014-02-18	13,124,932	$0.00	1,614,382	$0.00
Common Stock	Series B Preferred Stock	Disposition	2014-02-18	2,116,562	$0.00	260,340	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect

Footnotes

Every 8.13 shares of Series A Preferred Stock automatically converted into 1 share of Common Stock without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.
Shares held by Sofinnova Capital VI FCPR. The Reporting Person shares voting and investment power with respect to the shares held by Sofinnova Capital VI FCPR and disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein.
Every 8.13 shares of Series B Preferred Stock automatically converted into 1 share of Common Stock without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.
The shares were purchased at the Issuer's initial public offering.